You have accessJournal of UrologyBladder Cancer: Upper Tract Tumors II1 Apr 2014MP77-11 ENDOTHELIAL EXPRESSION OF ENDOGLIN IN UPPER URINARY TRACT UROTHELIAL CARCINOMA IS ASSOCIATED WITH INTRAVESICAL RECURRENCE AFTER RADICAL NEPHROURETERECTOMY Kazutoshi Fujita, Motohide Uemura, Akira Nagahara, Yasutomo Nakai, Go Tanigawa, Masahiro Nakagawa, Ryoichi Imamura, Wataru Nakata, Mototaka Sato, Koki Shimazu, Hiroaki Fushimi, Seiji Yamaguchi, and Norio Nonomura Kazutoshi FujitaKazutoshi Fujita More articles by this author , Motohide UemuraMotohide Uemura More articles by this author , Akira NagaharaAkira Nagahara More articles by this author , Yasutomo NakaiYasutomo Nakai More articles by this author , Go TanigawaGo Tanigawa More articles by this author , Masahiro NakagawaMasahiro Nakagawa More articles by this author , Ryoichi ImamuraRyoichi Imamura More articles by this author , Wataru NakataWataru Nakata More articles by this author , Mototaka SatoMototaka Sato More articles by this author , Koki ShimazuKoki Shimazu More articles by this author , Hiroaki FushimiHiroaki Fushimi More articles by this author , Seiji YamaguchiSeiji Yamaguchi More articles by this author , and Norio NonomuraNorio Nonomura More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2474AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Endoglin (CD105) is a type I homodimeric integral trasnmenbrane glycoprotein and accessory TGF-beta receptor. Endoglin is highly expressed on endothelial cells during tumor angiogenesis and inflammation. Endoglin levels in serum or urine have been reported as biomarkers in several cancers. Anti-endoglin therapy was also developed and now under the clinical trial. In the current study, we evaluated the expression status and prognostic significance of endoglin in upper urinary tract urothelial carcinoma (UTUC). METHODS Archival fomain-fixed and paraffin-embedded tissues from 99 primary UTUCs were retrieved. Tissued microarrays were constructed with triplicate tumor samples and paired nonneoplastic urothelium. Tissue microarrays were analyzed using immunohistochemistry for endoglin; association with clinicopathological parameters and outcome was studied. RESULTS We found that endoglin was expressed in the endothelium and significantly highly in UTUC compared with paired benign urothelium (P<0.05). Endoglin expression was not associated with pathological T stage or tumor grade. Whereas endoglin expression was not associated with increased hazard ratios for cancer-specific mortality or tumr recurrence in lymph node or distant metastasis, endolign expression was associated with intravesical recurrence, when adjusting for relevant clinicopathologic variables (P <0.05). CONCLUSIONS Upregulation of endolglin was observed in the endothelium of UTUC compared with normal urothelium, and associated with intravesical recurrence. The endoglin could be a biomarker to predict the intravesical recurrence as well as the therapeutic target. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e915-e916 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Kazutoshi Fujita More articles by this author Motohide Uemura More articles by this author Akira Nagahara More articles by this author Yasutomo Nakai More articles by this author Go Tanigawa More articles by this author Masahiro Nakagawa More articles by this author Ryoichi Imamura More articles by this author Wataru Nakata More articles by this author Mototaka Sato More articles by this author Koki Shimazu More articles by this author Hiroaki Fushimi More articles by this author Seiji Yamaguchi More articles by this author Norio Nonomura More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...